Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wu, W. et al. An electroencephalographic signature predicts antidepressant response in major depression. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0397-3 (2020).
Nilsonne, G. & Harrell, F. Jr. EEG-based model and antidepressant response. Nat. Biotechnol. https://doi.org/10.1038/s41587-020-00768-5 (2020).
Chekroud, A. M. et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 3, 243–250 (2016).
De Vries, Y. A. et al. Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. Br. J. Psychiatry 208, 515–521 (2016).
Harrell Jr, F. E. & Slaughter, J. C. Biostatistics for Biomedical Research http://hbiostat.org/doc/bbr.pdf (2020).
Bantis, L. Restricted cubic spline. MATLAB Centreal File Exchange. https://www.mathworks.com/matlabcentral/fileexchange/41241-restricted-cubic-spline (2020).
Chandler, G. M. et al. Validation of the Massachusetts General Hospital antidepressant treatment history questionnaire (ATRQ). CNS Neurosci. Therapeutics 16, 322–325 (2020).
W.W. receives salary and equity from Alto Neuroscience. Over the past 3 years, D.A.P. received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Otsuka and Takeda Pharmaceuticals as well as an honorarium from Alkermes. In addition, he has received stock options from BlackThorn Therapeutics. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. M.H.T. has served as an adviser or consultant for Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephalon, Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus and Wyeth-Ayerst Laboratories; he has received grants or research support from the Agency for Healthcare Research and Quality, Cyberonics, NARSAD, NIDA and NIMH. A.E. receives salary and equity from Alto Neuroscience and options for equity from Mindstrong Health, Akili Interactive Labs and Sizung for unrelated work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wu, W., Pizzagall, D.A., Trivedi, M.H. et al. Reply to: EEG-based model and antidepressant response. Nat Biotechnol 39, 28–29 (2021). https://doi.org/10.1038/s41587-020-0738-2